drugset
drugset / Trial / NCT01493570

Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP (Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male Volunteers

NCT01493570 ↗

Phase 1 Completed 20 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Due to the exploratory nature of this trial, there is no primary objective in a confirmatory sense. The study aims \- to evaluate the effect of different doses of BI 409306 on biomarker and to assess the exposure of BI 409306

Timeline

Start
2011-12-01
Primary completion
2012-02-01
Completion
2012-02-21

Drugs

EvaluationDrugModalityDoseRoute
Subject OSORESNONTRINE Small molecule 25 mg Oral
Subject OSORESNONTRINE Small molecule 50 mg Oral
Subject OSORESNONTRINE Small molecule 100 mg Oral
Subject OSORESNONTRINE Small molecule 200 mg Oral

Indications

No indication recorded.